ArticleHealth science reports2026
The Role of Immunoresolvents in Atherosclerosis: A Mini-Review on Their Biology and Therapeutic Opportunities.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Immunoresolvents in Atherosclerosis: A Mini-Review on Their Biology and Therapeutic Opportunities.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Atherosclerosis is a lipid-induced chronic inflammatory cardiovascular disorder denoted by the infiltration of immune cells and the agglomeration of lipids in the intima, the innermost layer, of the arteries of large and medium sizes. Defective efferocytosis is a sign of insufficient inflammation resolution that results in the agglomeration of secondarily necrotic macrophages and foam cells, and constitutes an advanced lesion having a necrotic lipid core, indicating plaque vulnerability. The inflammation resolution is an active, highly coordinated process governed by specialized pro-resolving lipid mediators (SPMs) or immunoresolvents, a group of bioactive lipid mediators that encompass arachidonic acid-derived lipoxins, omega-3 fatty acid eicosapentaenoic acid-derived E-series resolvins, docosahexaenoic acid-derived D-series resolvins, protectins, and maresins. These endogenously produced lipid mediators are resolution ligands functioning on distinct G-protein coupled receptors, thereby exhibiting the anti-inflammatory and pro-resolving effects, restoring tissue homeostasis and healing. Given the involvement of lipids and their pro- and anti-inflammatory derivatives in the pathogenesis of inflammatory states such as atherosclerosis, in this mini-review, we have tried to give a glance at the role of immunoresolvents in illness pathophysiology and the potential for pro-resolving therapeutics in atherosclerosis. Methods: This mini-review utilized published papers available in electronic databases, including PubMed, Science Direct, and Google Scholar, to recognize pertinent sources through the following search key terms: "Atherosclerosis," "SPM," "Immunoresolvent," "Lipoxin," "Resolvin," "Protectin," and "Maresin" until February 2026. Results: Recent investigations have shown that imbalances between pro-inflammatory lipid mediators and immunoresolvents are intimately linked to failed resolution and several common human disorders, including atherosclerosis. Moreover, dysregulation of resolving inflammation in atherosclerosis and other inflammatory diseases has been delineated in recent decades. Conclusion: Taken together, immunoresolvents could be regarded as new and hopeful therapeutic agents to be studied and utilized for treating atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.